January 30, 2017
Cambridge, USA

Duchenne Research Fund Provides Grant To Solid For Novel DMD Work

The Duchenne Research Fund (DRF) provided Solid with a generous research grant of $600,000 to support its LTBP4 program to combat fibrosis and to support novel biomarker work that may significantly improve the drug development and clinical trial process. This grant marks an additional milestone in Solid’s ongoing partnership with the UK-based charity.

“The Duchenne Research Fund is very excited to support these innovative projects with Solid Biosciences as they are addressing some of the major challenges in DMD research,” said Ronald Cohn, MD, FACMG, head of the DRF’s Scientific Advisory Board. “Treatments that target fibrosis will be necessary to maintain or even reverse functional deficits in boys with DMD. In addition, the development of novel biomarkers to help better inform the design and execution of clinical trials has the potential to revolutionize how we analyze any future therapies for this disease.”

Solid added the LTBP4 program to its research pipeline in 2016, a collaboration with Dr. Beth McNally’s lab at Northwestern University, to better understand the compound’s potential to reduce signs of muscle disease and increase overall function. It is believed that the protein LTBP4 prevents the activation of a key biological pathway (called TGF-beta), an important factor in inflammation and fibrosis. In a natural history study of Duchenne patients, the presence of a modified version of this LTBP4 protein correlated with patients’ ability to walk until later ages. If successful, this approach may be complimentary therapy to our Gene therapy treatment.

Solid is also exploring novel less invasive biomarkers, which aim to advance the entire field of drug development for Duchenne. This work includes non-invasive imaging, activity monitoring and blood-based biomarkers. These efforts aim to enable a greater population of non-ambulatory patients to participate in clinical trials, minimize the physical and emotional toll of invasive biopsies, and more sensitively capture functional changes.

“In this industry, we have learned that coming together to form alliances can change history,” said Gilad Hayeem, president of Solid Biosciences. “The DRF’s sophisticated and well-informed leadership recognizes the challenging landscape for drug approval. Through their commitment to help fund Solid’s biomarker and LTBP4 compound work, we hope we will advance the entire field of drug development for Duchenne.”





Related news


We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.


Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial


Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.


Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day


Today we are excited to announce the initiation of our first clinical trial for SGT-001.


We are getting ready to initiate a clinical study for our gene transfer candidate, SGT-001, later this year.


Solid Biosciences is pleased to announce additional research grant from our Australia-based partner Save Our Sons and an initial research grant from Ireland-based Join Our Boys.


Grant from Duchenne UK to fund research to better understand the potential benefits of statins in patients with Duchenne muscular dystrophy (DMD).


Biologic candidate has the potential to complement gene therapy by improving muscle function.


It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.


More information about Solid?

Please subscribe to receive our latest news